SCHEMBL3602689

SCHEMBL3602689

Cc1c(Cl)cccc1S(=O)(=O)Nc1nc(CCCl)cs1

nearest known ligand 0.66

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 9/20 0.66
HSD17B1 P14061 2/20 0.66
HSD17B2 P37059 2/20 0.66
KDM1A O60341 2/20 0.46
MAOA P21397 2/20 0.46
SLC40A1 Q9NP59 1/20 0.46
EDNRB P24530 2/20 0.46
EDNRA P25101 2/20 0.46
KMT2A Q03164 2/20 0.46
MEN1 O00255 1/20 0.46
POLB P06746 1/20 0.46
CCR4 P51679 1/20 0.44
ALDH1A1 P00352 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5911680 0.91 HSD11B1 (0.69) HSD11B1HSD17B1HSD17B2KDM1AMAOA
SCHEMBL4963665 0.91 HSD11B1 (0.69) HSD11B1HSD17B1HSD17B2KDM1AMAOA
SCHEMBL3614770 0.90 HSD11B1 (0.65) HSD11B1HSD17B1HSD17B2KDM1AMAOA
SCHEMBL3612077 0.90 HSD11B1 (0.68) HSD11B1HSD17B1HSD17B2KDM1AMAOA
SCHEMBL3619881 0.90 HSD11B1 (0.65) HSD11B1HSD17B1HSD17B2KDM1AMAOA
SCHEMBL3621003 0.89 HSD11B1 (0.64) HSD11B1HSD17B1HSD17B2KDM1AMAOA
Hydrochloric Acid SCHEMBL5693085 0.89 HSD11B1 (0.64) HSD11B1HSD17B1HSD17B2KDM1AMAOA
SCHEMBL5911760 0.89 HSD11B1 (0.67) HSD11B1HSD17B1HSD17B2KDM1AMAOA
SCHEMBL5911779 0.88 HSD11B1 (0.72) HSD11B1HSD17B1HSD17B2KDM1AMAOA
SCHEMBL3622383 0.88 HSD11B1 (0.66) HSD11B1HSD17B1HSD17B2KDM1AMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100113435-A1 INHIBITORS OF 11-BETA-HYDROXY STERIOD DEHYDROGENASE TYPE 1 BIOVITRUM AB 2010-05-06 US claimed
US-20100105714-A1 Furanone Compounds and Methods of Making and Using The Same BIOGEN IDEC MA INC. (US) 2010-04-29 US claimed
US-7618961-B2 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2009-11-17 US claimed
EP-1638553-A1 NEW USE I BIOVITRUM AB (SE) 2006-03-29 EP claimed
WO-2004112784-A1 NEW USE I BIOVITRUM AB (SE) 2004-12-29 WO claimed
US-20040224996-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2004-11-11 US claimed
EP-1283831-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2003-02-19 EP claimed
WO-2001090090-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2001-11-29 WO claimed
WO-2019075394-A1 COMPOUNDS FOR TREATMENT OF EMOTIONAL/PSYCHOLOGICAL SYMPTOMS IN FRAGILE X SYNDROME VANDERKLISH PETER (US) 2019-04-18 WO disclosed
US-20100113435-A1 INHIBITORS OF 11-BETA-HYDROXY STERIOD DEHYDROGENASE TYPE 1 BIOVITRUM AB 2010-05-06 US disclosed
US-20100105714-A1 Furanone Compounds and Methods of Making and Using The Same BIOGEN IDEC MA INC. (US) 2010-04-29 US disclosed
US-7618961-B2 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2009-11-17 US disclosed
EP-1638553-A1 NEW USE I BIOVITRUM AB (SE) 2006-03-29 EP disclosed
WO-2004112784-A1 NEW USE I BIOVITRUM AB (SE) 2004-12-29 WO disclosed
US-20040224996-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2004-11-11 US disclosed
EP-1283831-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2003-02-19 EP disclosed
WO-2001090090-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2001-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040224996-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD17B1, HSD11B2 HSD11B1 1/4885HSD17B1 2/4885HSD17B2 5/4885
US-20100105714-A1 Furanone Compounds and Methods of Making and Using The Same ALK, ACVR1, ACVR1B HSD11B1 370/4885HSD17B1 235/4885HSD17B2 368/4885
US-20100113435-A1 INHIBITORS OF 11-BETA-HYDROXY STERIOD DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD3B1 HSD11B1 1/4885HSD17B1 2/4885HSD17B2 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.